Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
weight loss
Biotech
Novo obesity prospect linked to ‘neuropsychiatric side effects’
Novo’s $1 billion bet that it had found a CB1 receptor blocker that could reduce weight while avoiding psychiatric effects faces new uncertainty.
James Waldron
Sep 20, 2024 10:25am
Biolexis enters small molecule into oral GLP-1 horse race
Sep 13, 2024 12:24pm
Roche hopes obesity drug will show 25% weight loss one day
Sep 11, 2024 11:45am
Tern oral GLP-1 shows 5% weight loss at one month, highest dose
Sep 9, 2024 9:13am
‘Not prudent’ for Novartis to join GLP-1 obesity race, says CEO
Jul 18, 2024 10:03am
Roche’s $2.7B weight-loss wager delivers early oral GLP-1 win
Jul 17, 2024 6:00am